Dr. Reddy's Laboratories has launched Fosaprepitant Injection in the U.S. Market, the therapeutic generic equivalent of EMEND (fosaprepitant) for injection, approved by the U.S. Food and Drug Administration (USFDA).
The EMEND for Injection brand had U.S. sales of approximately $279 million MAT for the most recent twelve months ending in July 2019 according to IQVIA Health.
Dr. Reddy's Fosaprepitant for Injection is available in 150 mg single-dose vial for reconstitution.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
